Clinical Trials Browser

Completed × Multiple Myeloma × selinexor × Clear all

NCT02199665 2025-11-03

SINE

Phase 1 Completed

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase 1/2 Completed

22 enrolled 16 charts

Multiple Myeloma

NCT02831686 2020-11-24

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Phase 1 Completed

Multiple Myeloma